ArticleOncology reports2026
TM6SF2 overexpression suppresses the proliferation and promotes apoptosis of human hepatocellular carcinoma cells.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transmembrane protein 6 superfamily member 2 (TM6SF2) is a potential tumor suppressor in hepatocellular carcinoma (HCC). At present, the role of TM6SF2 in HCC is poorly studied. The aim of the present study was to elucidate the potential role of TM6SF2 in hepatocellular carcinoma and its associated molecular mechanisms. The correlation between TM6SF2 and HCC progression was assessed using a bioinformatics approach. A TM6SF2‑overexpressing Huh‑7 cell model was constructed to examine the effects of TM6SF2 on cell proliferation, migration, invasion, cell‑cycle distribution, and apoptosis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of differentially expressed genes (DEGs) in the control Vector and TM6SF2 groups were performed using RNA sequencing (RNA‑Seq) data. Reverse transcription‑quantitative PCR and western blotting were used to verify the expression of candidate DEGs involved in cell cycle regulation and apoptosis. Overexpression of TM6SF2 inhibited HCC cell proliferation, invasion, and migration and promoted apoptosis. TM6SF2 overexpression induced S‑phase cell‑cycle arrest and promoted apoptosis in Huh‑7 cells. RNA‑Seq analysis showed that the majority of DEGs were involved in cell growth and biological processes, including the negative regulation of cell growth. KEGG pathway analysis identified the p53 signaling pathway as significantly enriched. Western blot analysis further showed increased levels of phosphorylated p53 and p21, suggesting p53‑related molecular changes. These findings suggest that TM6SF2 may exert anti‑tumor effects in Huh‑7 cells by inducing S‑phase cell‑cycle arrest and promoting apoptosis. The observed increases in phosphorylated p53 and p21 indicate that p53‑related molecular changes may be associated with TM6SF2 overexpression, although this requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.